Fiche publication
Date publication
janvier 2025
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Satoh T, Barthélémy P, Nogova L, Honda K, Hirano H, Lee KW, Rha SY, Ryu MH, Park JO, Doi T, Ajani J, Hangai N, Kremer J, Mina M, Liu M, Shitara K
Lien Pubmed
Résumé
Aberrant fibroblast growth factor receptor (FGFR)-driven signaling, predominantly arising from FGFR2 amplification, plays a key role in gastric cancer pathogenesis. This open-label, phase 2 study evaluated the efficacy and safety of futibatinib, an irreversible FGFR1-4 inhibitor, in patients with gastric or gastroesophageal junction (GEJ) cancer harboring FGFR2 amplifications.
Mots clés
FGFR2, Fibroblast growth factor receptor, Fibroblast growth factor receptor 2, Futibatinib, Gastric cancer, Gastroesophageal junction, Stomach cancer, TAS-120
Référence
Eur J Cancer. 2025 01 27;218:115262
